Recovering from the failure of an oral supplement to treat pulmonary arterial hypertension, United Therapeutics has received approval in France for an intravenous treatment.
The firm also has submitted a U.S. application for a standalone oral treatment.
French regulatory agency Agence Francaise de Securite Sanitaire des Produits de Sante has approved IV use of the Silver Spring company’s Remodulin.
Remodulin already is approved in most of Europe and in the U.S. for subcutaneous infusion treatment, or continuous injections just under the skin, according to United Therapeutics information.
To read the full, original article click on this link: Gazette.Net: France OKs United Therapeutics IV treatment
{iframe}http://www.gazette.net/article/20111227/NEWS/712279976/1033/united-therapeutics-gets-go-ahead-for-hypertension-treatment-in&template=gazette{/iframe}